OmniAb Expands xPloration Platform, Introduces OmniTides, and Highlights 19 Clinical Trials in Pipeline
Event summary
- OmniAb's xPloration platform, an AI-powered high-throughput single B-cell screening tool, will be commercially available starting October 2026, targeting a $500M market opportunity.
- The company introduced OmniTides, a peptide discovery platform leveraging its OmniUltra transgenic chicken technology.
- OmniAb anticipates 19 clinical trials involving its partner-derived drugs to reach primary completion by the end of 2026 or in 2027.
- xPloration revenue is projected to double annually, reaching $6M by 2028.
The big picture
OmniAb's expansion of its xPloration platform and introduction of OmniTides align with the broader industry shift toward AI-driven and high-throughput drug discovery solutions. The company's strategic focus on leveraging its proprietary technologies for sustainable growth positions it within the competitive biotech platform market, where success hinges on both technological differentiation and partner adoption.
What we're watching
- Revenue Growth
- Whether OmniAb can sustain the projected doubling of xPloration revenue annually through 2028.
- Clinical Success
- The pace at which OmniAb-derived drugs advance through clinical trials and their potential impact on milestone payments and royalties.
- Market Adoption
- How quickly the biotech industry embraces the xPloration platform and OmniTides, given the competitive landscape of lab automation and peptide discovery tools.
Related topics
